Company profile

MANNKIND CORP

NASDAQ:MNKDBiotechnology: Pharmaceutical Preparations

Drug pipeline (3)

Asset	Stage	Revenue	Trials	Status
AFREZZA	approved	—	6	approved
FUROSCIX	approved	—	5	approved
FUROSCIX READYFLOW (AUTOINJECTOR)	approved	—	5	approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (52)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT00511732	phase2	completed	2004-06-01	2005-08-01	Mannkind Corporation	18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 Diabetes
NCT00539396	phase2	completed	2005-03-01	—	Mannkind Corporation	A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine
NCT00475371	phase1	completed	2007-04-01	2007-06-01	Mannkind Corporation	A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males
NCT00570687	phase2	completed	2007-09-01	2009-01-01	Mannkind Corporation	A Study Comparing Subcutaneous Rapid Acting Insulin and One Formulation of Inhaled Insulin in Subjects With Type 2 Diabetes
NCT00662857	phase2	completed	2008-04-01	2008-11-01	Mannkind Corporation	A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

FDA applications (2)

Application

Approved

Type

Applicant

Products

NDA 209988

2022-10-07

NDA

SCPHARMACEUTICALS INC A WHOLLY OWNED SUB OF MANNKIND CORP

BLA 022472

2014-06-27

BLA

MANNKIND CORPORATION